IP Library Granted Patent US 12,735,402
Granted Patent B2
US 12,735,402 · App. 19/309,326 · Granted Sep 15, 2026

PAI-1 inhibitors and uses thereof

Inventors: Vara Prasad Josyula (Cleveland, OH); Thaddeus Stappenbeck (Cleveland, OH)
Assignee: The Cleveland Clinic Foundation
C07D401/14A61K31/357A61K31/4155A61K31/416A61K31/4192A61K31/422A61K31/4245A61K31/437A61K31/4439A61K31/444A61K31/454A61K31/4545A61K31/4709A61K31/497A61K31/501A61K31/506A61K31/513A61P1/00C07D213/80C07D215/12C07D231/12C07D231/40C07D261/08C07D319/16C07D401/04C07D401/12C07D403/10C07D403/12C07D405/04C07D405/12C07D405/14C07D413/04C07D413/10C07D413/12C07D413/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,402
App. No.
19/309,326
Granted
Sep 15, 2026
Kind
B2
Abstract

Disclosed herein are compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting PAI-1 using the compounds, and methods of treating IBDs using the compounds.

Claims (67)

1 . A compound of formula (Ia):

or a pharmaceutically acceptable salt thereof, wherein:

R 2 is H, halo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, or C 1 -C 4 haloalkoxy;

R 3 is H, halo, or C 1 -C 4 alkyl;

wherein R 2 and R 3 are optionally taken together with the carbon atoms to which they are attached to form a 5-or 6-membered ring optionally substituted with 1 or 2 substituents independently selected from C 1 -C 4 alkyl, halo, and oxo;

X 6 is CR 6 or N;

R 6 is H, halo, or C 1 -C 4 alkyl; and

R 8 is a group of formula:

wherein R x is —(CH 2 ) n —Y or a monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from O and N, wherein the monocyclic heterocyclyl is unsubstituted or substituted with 1 C 1 -C 4 alkyl group, wherein n is 1 or 2, and Y is selected from —COOR g and —NR h R i , wherein R g , R h , and R i are each independently selected from H and C 1 -C 4 alkyl.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 is H, halo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, or C 1 -C 4 haloalkoxy; and

R 3 is H, halo, or C 1 -C 4 alkyl.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 6 is CR 6 and R 6 is H.

4 . The compound of claim 1 , wherein the compound is selected from:

4-chloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-chloro-benzoic acid,

2-[[3-(1-tetrahydropyran-4-ylpyrazol-3-yl)benzoyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,

2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-methyl-benzoic acid,

4-methyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-methyl-benzoic acid,

2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-4-(trifluoromethyl)benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-(trifluoromethyl)benzoic acid,

2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]-4-(trifluoromethyl)benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-(trifluoromethyl)benzoic acid,

4-isopropyl-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-isopropyl-benzoic acid,

4-isopropyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-isopropyl-benzoic acid,

4-tert-butyl-2-[[3-(1-tetrahydropyran-4-ylpyrazol-3-yl)benzoyl]amino]benzoic acid,

4-tert-butyl-2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,

4-tert-butyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,

4-tert-butyl-2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]benzoic acid,

4-methoxy-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-methoxy-benzoic acid,

4-methoxy-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-methoxy-benzoic acid,

2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-4-(trifluoromethoxy)benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-(trifluoromethoxy)benzoic acid,

2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]-4-(trifluoromethoxy)benzoic acid,

2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-(trifluoromethoxy)benzoic acid,

4,5-dichloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,

2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4,5-dichloro-benzoic acid,

3-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]naphthalene-2-carboxylic acid,

3-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]naphthalene-2-carboxylic acid,

6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carboxylic acid,

[6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carbonyl]oxysodium,

6-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carboxylic acid,

6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-1,3-benzodioxole-5-carboxylic acid,

5-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-1H-indazole-6-carboxylic acid,

1-methyl-5-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]indazole-6-carboxylic acid,

5-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-1H-indazole-6-carboxylic acid,

5-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-1-methyl-indazole-6-carboxylic acid,

2-[[3-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]benzoyl]amino]benzoic acid,

2-[[3-[1-(4-piperidyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,

2-[[3-[1-(1-methyl-4-piperidyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,

sodium 4,5-dichloro-2-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)picolinamido)benzoate, and

sodium 7-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)picolinamido)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate,

and pharmaceutically acceptable salts thereof.

5 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6 . A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7 . A compound:

4-chloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,

or a pharmaceutically acceptable salt thereof.

8 . A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 26, 2026
From: CLEVELAND CLINIC FOUNDATION
To: UNITED STATES GOVERNMENT
Reel/Frame 074489/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: JOSYULA, VARA PRASAD; STAPPENBECK, THADDEUS
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 072743/0149 →
Continuity (2)
Provisional Application 63759889 · Feb 18, 2025
Related Publication 20260242355A1 · Aug 20, 2026
References Cited (104)
US 5731328A · Berg et al. · 1998 [cited by applicant]
US 5763483A · Bischofberger et al. · 1998 [cited by applicant]
US 5952375A · Bischofberger et al. · 1999 [cited by applicant]
US 6270766B1 · Feldman et al. · 2001 [cited by applicant]
US 7057086B2 · Vaughan et al. · 2006 [cited by applicant]
US 7741356B2 · Breslin et al. · 2010 [cited by applicant]
US 7786158B2 · Breslin et al. · 2010 [cited by applicant]
US 7846442B2 · Feldmann et al. · 2010 [cited by applicant]
US 8344011B2 · Breslin et al. · 2013 [cited by applicant]
US 8609709B2 · Breslin et al. · 2013 [cited by applicant]
US 9387206B2 · Cohen et al. · 2016 [cited by applicant]
US 9427438B2 · Alam · 2016 [cited by applicant]
US 9527878B2 · Lawrence et al. · 2016 [cited by applicant]
US 9845327B2 · Krainc et al. · 2017 [cited by applicant]
US 10092537B2 · Ando et al. · 2018 [cited by applicant]
US 11007179B2 · Costello et al. · 2021 [cited by applicant]
US 11090291B2 · Costello et al. · 2021 [cited by applicant]
US 11160792B2 · Costello et al. · 2021 [cited by applicant]
US 11311516B2 · Costello et al. · 2022 [cited by applicant]
US 20080188540A1 · Tesconi et al. · 2008 [cited by applicant]
US 20080188543A1 · Thakur et al. · 2008 [cited by applicant]
US 20090042918A1 · Kearney · 2009 [cited by examiner]
US 20110105574A1 · Fleenor et al. · 2011 [cited by applicant]
US 20120022080A1 · Miyata · 2012 [cited by examiner]
US 20130165473A1 · Duggan · 2013 [cited by applicant]
US 20130289086A1 · Duggan · 2013 [cited by applicant]
US 20130309690A1 · Ringe et al. · 2013 [cited by applicant]
US 20140296256A1 · Miyata et al. · 2014 [cited by applicant]
US 20150361063A1 · Ringe et al. · 2015 [cited by applicant]
US 20180042922A1 · Cheruvu et al. · 2018 [cited by applicant]
US 20200147007A1 · Lawrence et al. · 2020 [cited by applicant]
US 20200165677A1 · Stappenbeck et al. · 2020 [cited by applicant]
US 20200330592A1 · Black · 2020 [cited by applicant]
US 20220340665A1 · Ando et al. · 2022 [cited by applicant]
AU 2017336363A1 · 2019 [cited by applicant]
CN 101386619A · 2009 [cited by applicant]
EP 2473166A2 · 2012 [cited by applicant]
EP 3752201A1 · 2020 [cited by applicant]
EP 3875078A1 · 2021 [cited by applicant]
JP H1072413A · 1998 [cited by applicant]
JP H11255895A · 1999 [cited by applicant]
JP 2001206948A · 2001 [cited by applicant]
JP 2002080596A · 2002 [cited by applicant]
JP 2020012104A · 2020 [cited by applicant]
WO WO2003006443A2 · 2003 [cited by applicant]
WO WO2004018414A2 · 2004 [cited by applicant]
WO WO2006039356A2 · 2006 [cited by applicant]
WO WO2006062093A1 · 2006 [cited by applicant]
WO WO2009038842A2 · 2009 [cited by applicant]
WO WO2010087430A1 · 2010 [cited by applicant]
WO WO2010113022A1 · 2010 [cited by applicant]
WO WO2010141932A1 · 2010 [cited by applicant]
WO WO2011057110A1 · 2011 [cited by applicant]
WO WO2012008543A1 · 2012 [cited by applicant]
WO WO2014171464A1 · 2014 [cited by applicant]
WO WO2020009016A1 · 2020 [cited by applicant]
WO WO2020056191A1 · 2020 [cited by applicant]
WO WO2020163966A1 · 2020 [cited by applicant]
WO WO2021235532A1 · 2021 [cited by applicant]
Cas Registration No. 2248871-73-8 ( filed on Nov. 18, 2018, Chemcats, Chemical Library Supplier (Year: 2018). [cited by examiner]
Cas Registration No. 2921455-78-7 ( filed on Apr. 23, 2023, Chemcats, Chemical Library Supplier (Year: 2023). [cited by examiner]
Anderson K.D., et al., “A Controlled Trial of Corticosteroids in Children with Corrosive Injury of the Esophagus”, The New England Journal of Medicine, Sep. 6, 1990, vol. 323, No. 10, pp. 637-640. [cited by applicant]
Arevalo-Silva C., et al., “Ingestion of Caustic Substances: a 15-year Experience”, The Laryngoscope, Aug. 2006, vol. 116, No. 8, pp. 1422-1426. [cited by applicant]
Axon Medchem: “T 1776Na Axon 1769”, Retrieved Nov. 12, 2025, 5 pages. [cited by applicant]
Baddawy H.A., et al., “Synthesis and Reactions of N-Hydroxy-1-phenylnaphthalene-2,3-dicarboximide”, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980, vol. 19B, No. 2, pp. 112… [cited by applicant]
Bio Techne Ltd: “Sk 216”, Catalog #: 6187, Retrieved Nov. 25, 2025, 5 pages. [cited by applicant]
Bio Techne Ltd: “TM5275 Sodium Salt”, Catalog #: 5769, Retrieved Nov. 12, 2025. 4 pages. [cited by applicant]
Borja A.R., et al., “Lye Injuries of the Esophagus Analysis of Ninety Cases of Lye Ingestion”, The Journal of Thoracic and Cardiovascular Surgery, Apr. 1969, vol. 57, No. 4, pp. 533-538. [cited by applicant]
Chen D., et al., “Structure-Based Redesign of an Edema Toxin Inhibitor”, Bioorganic & Medicinal Chemistry, Jan. 1, 2012, vol. 20, No. 1, pp. 368-376 (19 Pages). [cited by applicant]
Cheng H-T., et al., “Profiling of Inflammatory Cytokines in Patients with Caustic Gastrointestinal Tract Injury”, PLoS One, Nov. 18, 2021, vol. 16, No. 11, e0260012, pp. 1-12. [cited by applicant]
Cho W., et al., “Dual Changes in Conformation and Optical Properties of Fluorophores Within a Metal-organic Framework During Framework Construction and Associated Sensing Event”, Journal of the American Chemical Society… [cited by applicant]
Dalapati R., et al., “A Pyrene-Functionalized Metal-Organic Framework for Nonenzymatic and Ratiometric Detection of Uric Acid in Biological Fluid via Conformational Change”, Inorganic Chemistry, 2019, vol. 58, No. 9, pp… [cited by applicant]
El-Sayed R.A., et al., “Synthesis and Antimicrobial Activity of some new 4-phenyl-2-(o-, m- and p-carboxyphenyl)-5.6-benso-1:3-Isoindolindione Amino Acid and Peptide Derivatives”, Proceedings of the Indian National Scie… [cited by applicant]
Esbriet: “(Pirfenidone) Tablets”, Retrieved Nov. 12, 2025, 4 pages. [cited by applicant]
Grantome: “Preclinical Development of a First in Class Therapeutic for Treating Idiopathic Pulmonary Fibrosis”, 2019, Mdi Therapeutics Inc, Retrieved Nov. 12, 2025, 2 pages. [cited by applicant]
Gummin D.D., et al., “2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report”, Clinical Toxicology (Phila), Dec. 2020, vol. 58, No. 12, pp. 1360-… [cited by applicant]
Hamed A.A., et al., “Synthesis of benzo[g]quinazoline-2,4-diones via Lossen Rearrangement of N-(arylsulphonyloxy)naphthalene-2,3-Dicarboximide Derivatives”, India Journal of Chemistry, Section B: Organic Chemistry Inclu… [cited by applicant]
Hosaka S., et al., Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance, Front Pharmacology, Jun. 24, 2020, vol. 11, N… [cited by applicant]
Huang W-T., et al., “Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor-1 for Lung Fibrosis”, American Journal of Respiratory Cell and Molecular Biology, Jan. 2012, vol. 46, No. 1, pp. 87-9… [cited by applicant]
International Search Report and Written Opinion for PCT/US2025/043386, Mailed Nov. 28, 2025, 13 pages. [cited by applicant]
Kemnitzer W., et al., “Discovery of N-aryl-9-oxo-9H-Fluorene-1-Carboxamides as a New Series of Apoptosis Inducers Using a Cell-and Caspase-based High-throughput Screening Assy. 1. Structure-Activity Relationships of the… [cited by applicant]
Khalaf N.S., et al., “Synthesis and Antimicrobial activity of some new 4-phenyl-2-(0-, m-, & p-carboxyphenyl)-5:6-benxo-1:3-Isoindolindione Amino Acid and Peptide Derivatives”, AL-Azhar Bulletin of Science, 1996, vol. 7… [cited by applicant]
Kobak K.A., et al., “Determining the Contributions of Protein Synthesis and Breakdown to Muscle Atrophy Requires Non-steady-state Equations”, Journal of Cachexia, Sarcopenia and Muscle, Dec. 2021, vol. 12, vol. 6, pp. 1… [cited by applicant]
Kochhar R., et al., “Corrosive Induced Carcinoma of Esophagus: Report of Three Patients and Review of Literature”, Journal of Gastroenterology and Hepatology, Apr. 2006, vol. 21, No. 4, pp. 777-780. [cited by applicant]
Li Y., et al., “Nationwide Estimate of Emergency Department Visits in the United States Related to Caustic Ingestion”, Diseases of the Esophagus, Jun. 15, 2020, vol. 33, No. 6, doaa012, pp. 1-9. [cited by applicant]
MedChemExpress (MCE): “Loureirin B”, Master of Bioactive Molecules, Retrieved Nov. 12, 2025, 5 pages. [cited by applicant]
MedChemExpress (MCE): “Tiplaxtinin (synonyms: PAI-039; Tiplasinin)”, Master of Bioactive Molecules,, Retrieved Nov. 12, 2025, 5 pages. [cited by applicant]
MedChemExpress (MCE): “TM5441”, PAI-1 Inhibitor, Master of Bioactive Molecules, Retrieved Nov. 12, 2025, 5 pages. [cited by applicant]
MedChemExpress (MCE): “Toddalolactone”, PAI-1 Inhibitor, Master of Bioactive Molecules, Retrieved Nov. 12, 2025, 4 pages. [cited by applicant]
MedKoo Biosciences Inc: “MedKoo Cat#319882”, Aleplasinin, Retrieved Nov. 12, 2025, 3 pages. [cited by applicant]
Michigan Medicine: “Fast Forward Medical Innovation”, MedigenixBio, University of Michigan Website, Retrieved Nov. 12, 2025, 18 pages. [cited by applicant]
Ofev (nintedanib)capsules 150mg, Boeringer Ingelheim, Retrieved Nov. 12, 2025, 6 pages. [cited by applicant]
Okonta K.E., et al., “In Patients with Corrosive Oesophageal Stricture for Surgery, is Oesophagectomy Rather than Bypass Necessary to Reduce the Risk of Oesophageal Malignancy”, Interactive Cardio Vascular and Thoracic … [cited by applicant]
Park J., et al., “Micro-Crystals of Metal-organic Frameworks Constructed from Pyrene-based Organic Linkers and Lanthanide Ions for Tunable White Light Emission”, CrystEngComm, 2016, vol. 18, No. 43, pp. 8372-8376. [cited by applicant]
Placencio V.R., et al., “Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity”, PLoS One, Jul. 24, 2015, vol. 10, No. 7, e0133786, pp. 1-18. [cited by applicant]
PubChem SID: 479346291, Substance Record Z6291484506, Modify date Apr. 25, 2023, 5 Pages. [cited by applicant]
Rouch A., et al., “Small Molecules Inhibitors of Plasminogen Activator Inhibitor-1—An Overview”, European Journal of Medicinal Chemistry, Mar. 6, 2015, vol. 92, pp. 619-636. [cited by applicant]
Santa Cruz: “Geodin (CAS 427-63-4)”, Santa Cruz Animal Health, Retrieved Nov. 12, 2025, 3 pages. [cited by applicant]
SciFinder, American Chemical Society (ACS), 2020, 16 pages. [cited by applicant]
SciFinder, American Chemical Society (ACS), 2020, 5 pages. [cited by applicant]
Sprogyte L., et al., “Pathogenesis of Alkali Injury-Induced Limbal Stem Cell Deficiency: A Literature Survey of Animal Models”, Cells, May 1, 2023, vol. 12, No. 9, 1294, pp. 1-21. [cited by applicant]
Togo H., et al., “Synthesis of New Photosensitive Polyimides Containing Pendant Proparhyl Ester Groups”, Journal of Photopolymer Science and Technology, 1999, vol. 12, No. 2, pp. 223-230 (7 Pages). [cited by applicant]
Wang Y., et al., “Pan-Transciptome-based Candidate Therapeutic Discovery for Idiopathic Pulmonary Fibrosis”, bioRxiv, 10.1101/824367, Jun. 29, 2020, 35 pages. [cited by applicant]
Yamaoka N., et al., “Identification of Novel Plasminogen Activator Inhibitor-1 Inhibitors with Improved Oral Bioavailability: Structure Optimization of N-acylanthranilic Acid Derivatives”, Bioorganic & Medicinal Chemist… [cited by applicant]